Xilio Therapeutics 10-Q (11/9/22)

Note: Xilio described the IRA in a risk section entitled “Current and future legislative efforts may limit the prices for our products, if and when they are licensed for marketing, and that could materially impact our ability to generate revenues”

Scroll to Top